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Outcomes of Outpatient Parenteral Antimicrobial 
Therapy With Ceftriaxone for Methicillin-Susceptible 
Staphylococcus aureus Bloodstream Infections—A Single-
Center Observational Study
Yasir Hamad , Lee Connor, Thomas C. Bailey, and Ige A. George
Division of Infectious Diseases, Washington University School of Medicine, St. Louis, Missouri, USA
Background.  Staphylococcus aureus bloodstream infections (BSIs) are associated with significant morbidity and mortality. 
Ceftriaxone is convenient for outpatient parenteral antimicrobial therapy (OPAT), but data for this indication are limited.
Methods.  Adult patients with methicillin-susceptible Staphylococcus aureus (MSSA) BSI discharged on OPAT with cefazolin, 
oxacillin, or ceftriaxone for at least 7 days were included. We compared outcomes of ceftriaxone vs either oxacillin or cefazolin. 
Ninety-day all-cause mortality, readmission due to MSSA infection, and microbiological failure were examined as a composite out-
come and compared among groups. Rates of antibiotic switches due to intolerance were assessed.
Results.  Of 243 patients included, 148 (61%) were discharged on ceftriaxone and 95 (39%) were discharged on either oxacillin 
or cefazolin. The ceftriaxone group had lower rates of intensive care unit care, endocarditis, and shorter duration of bacteremia, but 
higher rates of cancer diagnoses. There was no significant difference in the composite adverse outcome in the oxacillin or cefazolin 
group vs the ceftriaxone group (18 [19%] vs 31 [21%]; P = .70), comprising microbiological failure (6 [6.3%] vs 9 [6.1%]; P = .94), 
90-day all-cause mortality (7 [7.4%] vs 15 [10.1%]; P =  .46), and readmission due to MSSA infection (10 [10.5%] vs 13 [8.8%]; 
P = .65). Antibiotic intolerance necessitating a change was similar between the 2 groups (4 [4.2%] vs 6 [4.1%]; P = .95).
Conclusions.  For patients with MSSA BSI discharged on OPAT, within the limitations of the small numbers and retrospective de-
sign we did not find a significant difference in outcomes for ceftriaxone therapy when compared with oxacillin or cefazolin therapy.
Keywords.  cefazolin; ceftriaxone; MSSA bacteremia; OPAT; oxacillin.
Staphylococcus aureus is a leading cause of both community-
onset and hospital-acquired bloodstream infections (BSIs) [1]. 
S.  aureus BSI is often associated with complications such as 
dissemination to distant sites and endocarditis, consequently 
leading to morbidity and mortality [2]. Due to the risk of re-
currence, prolonged parenteral therapy with a beta-lactamase-
resistant penicillin (nafcillin or oxacillin) or cefazolin is the 
guideline-suggested care to treat methicillin-susceptible S. au-
reus (MSSA) BSI [3]. Ceftriaxone has been shown to be an 
effective treatment for serious MSSA infections in previous 
studies and has a Food and Drug Administration–labeled indi-
cation for MSSA septicemia [4, 5]. A retrospective study of 124 
patients with MSSA bone and joint infections at our institution 
comparing ceftriaxone vs oxacillin found that ceftriaxone had 
similar rates of success and was better tolerated than oxacillin 
[6]. Few studies have compared ceftriaxone with either nafcillin 
or cefazolin in MSSA BSIs. In a study by Patel et  al., clinical 
and microbiological cure rates were similar among 51 patients 
treated with nafcillin or cefazolin and 42 patients treated with 
ceftriaxone [7]. Carr et al. reported more adverse outcomes in 
33 patients with MSSA BSI treated with ceftriaxone compared 
with 38 treated with cefazolin, but the 2 groups were different, 
with many of the patients in the ceftriaxone group being sent to 
skilled nursing facilities that had higher readmission rates [8].
The optimal choice of beta-lactam therapy for MSSA blood-
stream infection is unclear. When compared with nafcillin, ox-
acillin, or cefazolin, ceftriaxone has benefits in terms of lower 
costs, once- or twice-daily administration, and a favorable 
long-term side effect profile, making it an attractive drug for 
outpatient parenteral antibiotic therapy (OPAT) [4, 6]. Whether 
once- or twice-daily ceftriaxone therapy results in acceptable 
outcomes for patients with MSSA BSI is an open question [9, 
10]. This study compared outcomes of MSSA BSI among pa-
tients discharged on ceftriaxone compared with oxacillin or 
cefazolin.
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METHODS
Study Design and Patient Population
We performed a retrospective cohort study of adults with 
MSSA BSI who were discharged from Barnes-Jewish Hospital 
on OPAT and followed by the Washington University 
Infectious Disease service over a 4.5-year period from 
December 1, 2014, to April 30, 2019. Barnes-Jewish Hospital 
is a 1350-bed tertiary care medical center located in St. Louis, 
Missouri. Patients were identified from the OPAT registry, 
which includes all patients who are seen by Infectious Disease 
physicians and discharged on parenteral antibiotics. Patients 
were included if they had ≥1 positive blood culture for MSSA 
and were discharged on 1 of the 3 antibiotics of interest: 
ceftriaxone 2–4 g daily, oxacillin 2 g every 4 hours, or cefazolin 
2 g every 8 hours or equivalent, adjusted for renal injury (of 
note, nafcillin is not on the hospital formulary). If the patient 
had multiple admissions for MSSA BSI, the first admission 
was included as the index admission. Patients were excluded 
if they had polymicrobial bloodstream infections, had <7 days 
of OPAT, or had end-stage renal disease (ESRD) on hemodial-
ysis (HD). HD patients were excluded as they could have been 
preferentially treated with either cefazolin due to the ease of 
dosing or ceftriaxone, given that its main route of excretion 
is not renal. Patients were identified from the Washington 
University Infectious Diseases OPAT database. All patients 
were seen by Infectious Disease providers during the index 
hospitalization.
Clinical Data Collection
Clinical data were collected through review of inpatient and 
outpatient electronic medical records using Research Electronic 
Data Capture (REDCap) electronic data capture tools hosted at 
Washington University in St Louis. REDCap is a secure, Web-
based software platform designed to support data capture for 
research studies [11]. Clinical data abstracted by 3 authors 
(L.C., Y.H., I.A.G.) included demographic characteristics, pa-
tient comorbidities, clinical presentation, diagnostic evalu-
ations (including laboratory results, microbiology results, and 
imaging studies), antibiotics used, and planned duration of 
treatment. In addition, outpatient clinical parameters assessed 
in infectious diseases (at 2–3 weeks after discharge and/or at the 
end of therapy) and surgical subspecialty clinics included signs 
and symptoms of infection noted during the follow-up visit(s), 
documentation of adverse events related to antibiotic adminis-
tration, laboratory data, imaging studies, change or extension 
of intravenous (IV) antibiotics, and oral suppressive antibiotic 
recommendations. These data were used to determine whether 
there was evidence of successful treatment or treatment failure. 
Outcomes were compared between the 2 groups—those who 
received oxacillin or cefazolin vs those who received ceftriaxone 
on discharge.
Variable Definitions
Ninety-day all-cause mortality was defined as death occurring 
within 90 days of discharge determined by electronic medical 
record review. Clinical failure was defined as unanticipated 
readmission or surgical intervention related to MSSA infec-
tion within 90  days of discharge from the index admission. 
Microbiological failure was defined as subsequent isolation 
of MSSA from any sterile site within 90 days of completion of 
treatment. The composite outcome for treatment failure was 
defined by death or clinical or microbiological failure within 
the specified periods above.
Comorbid conditions were evaluated using the Elixhauser 
Comorbidity Index, which is based on the International 
Classification of Diseases, 9th and 10th Revisions, Clinical 
Modification (ICD-9-CM and ICD-10-CM), codes. ICD codes 
were supplemented by chart review to identify concurrent in-
fections including skin and soft tissue infections, endocarditis, 
and osteomyelitis, as well as ESRD, central line–associated 
bloodstream infections (CLABSIs), intravenous drug use, and 
the presence of prosthetic materials. The primary source of in-
fection was identified from concurrent positive microbiologic 
specimens for MSSA or based upon consistent clinical signs and 
symptoms and radiographic evidence. Endocarditis was defined 
by evidence of a vegetation on cardiac valves identified by ech-
ocardiography, along with concomitant MSSA bacteremia, or 
if the ID physician suspected infective endocarditis and a deci-
sion was made to treat as infective endocarditis. The Elixhauser 
Comorbidity Index (ECI), incorporating comorbidities to pre-
dict inpatient mortality, was used as a composite variable to 
associate risk factors for the composite outcome [12]. Source 
control was felt to be achieved if the reviewing physician ascer-
tained that the focus of infection had been removed (eg, abscess 
drained, central venous catheter removed).
Statistical Analysis
Descriptive statistics were used for the demographic and clinical 
characteristics of the study population. Categorical data were 
compared using the chi-square test or Fisher exact test, and 
continuous variables were compared using the Student t test or 
Mann-Whitney U test, as appropriate. Patients with proven or 
suspected endocarditis were evaluated as a subgroup, as these 
were potentially sicker patients. Potential risk factors for treat-
ment failure were analyzed for the 2 groups using univariable 
and multivariable Cox proportional hazards models. The pro-
portional hazards assumption was evaluated for the outcome 
variables using visual inspection of log-log survival curves 
[13]. For the multivariable model, variables were specified by 
selecting clinically meaningful factors that could potentially be 
associated with treatment failure, which included comorbidity 
indices, choice of antibiotics, discharge destination, source con-
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the time of last follow-up or 90 days post-treatment, whichever 
came first.
Statistical significance was set at P < .05. All analyses were 
performed using SAS 9.4 software (Cary, NC, USA).
Patient Consent Statement
The Washington University School of Medicine Human 
Research Protection Office (HRPO) approved this study. 
Informed consent was not required for this study according to 
the HRPO regulations given its minimal risk and retrospective 
study design.
RESULTS
During the study period, 243 patients with MSSA BSI received 
1 of the 3 antibiotics of interest for at least 7  days as part of 
OPAT. Of these, 148 (61%) received ceftriaxone while 95 (39%) 
patients received either oxacillin (56) or cefazolin (39). The 
mean age was 59.6 years, and patients were predominantly male 
(63%) and White (77%). The most common comorbidities 
were diabetes mellitus (59 [24%]), solid tumor (51 [21%]), val-
vular heart disease (50 [21%]), and congestive heart failure (49 
[20%]). Over a third of patients (89 [37%]) required intensive 
care unit care during the index hospitalization, including 40 
(16%) who required mechanical ventilation (Table  1). There 
were 15 (6.2%) patients who were lost to follow-up during the 
course of the study, 8 (5.4%) in the ceftriaxone group and 7 
(7.4%) in the oxacillin-cefazolin group.
Endocarditis complicated many of the BSIs, occurring in 83 
(34%) patients. MSSA bacteremias were associated with central 
venous catheters (CVCs) in 70 (29%) patients and bone and 
Table 1. Clinical Characteristics and Outcomes of 243 Patients in the Ceftriaxone and Oxacillin-Cefazolin Treatment Groups
Variable, No. (%) or Median (IQR) Total (n = 243) Oxacillin-Cefazolin (n = 95 [39%])  Ceftriaxone (n = 148 [61%]) P Value
Age, y 59.6 (47.8–70) 57.1 (46.4–68.2) 61.3 (48.9–71.5) .08
Sex (male) 154 (63.4)  61 (64.2) 93 (62.8) .83
Race (White) 187 (77.4) 73 (76.8) 115 (77.7) .88
Body mass index, kg/m2 29.1 (23.5–35.6) 29.1 (24.2–32.9) 27.3 (23.5–33.3) .84
AIDS 5 (2.1) 1 (1.1) 4 (2.7) .27
CHF 49 (20.6) 20 (21.7) 29 (19.9) .73
Diabetes 59 (24.3) 20 (21.1) 39 (26.4) .35
Acute renal failure in the past year 43 (18.1) 16 (17.4) 27 (18.5) .83
Solid tumors 51 (21) 8 (8.4) 43 (29.1) <.01
Hematological malignancies 14 (5.9) 6 (6.5) 8 (5.5) .74
Valvular heart disease 50 (21) 31 (33.7) 19 (13) <.01
Length of stay after positive blood culture 9.9 (6.6–16.2) 15.3 (9.9–20.8) 7.4 (5.5–12.2) <.01
Intensive care unit stay 89 (36.6) 46 (48.4) 43 (29.1) <.01
Recent hospitalization in the last 30 d 43 (17.7) 18 (19) 25 (16.9) .68
Ventilator support 40 (16.5) 20 (21.1) 20 (13.5) .12
Presence of CIED 23 (9.5) 12 (12.6) 11 (7.4) .18
CIED explanted 7 (30.4) 4 (33.3) 3 (27.3) .99
LVAD 6 (2.5) 2 (2.1) 4 (2.7) .32
Transthoracic echocardiography 228 (93.8) 86 (90.5) 142 (95.6) .09
Transesophageal echocardiography 93 (38.3) 56 (59) 37 (25) <.01
Source control not achieved 23 (9.5) 9 (9.5) 14 (9.5) .99
Total IV antibiotic course duration  42 (34–44) 42 (42–44) 42 (28–43) .01
Inpatient IV antibiotic duration  6 (4–11) 9 (5–15) 5 (4–9) <.01
OPAT duration  34 (24–39) 34 (27- 39) 34 (24–39) .70
Discharge to post–acute care facility 83 (34.2) 32 (33.7) 51 (34.5) .90
Bacteremia duration, d 1.5 (1–2.4) 1.7 (1–2.9) 1.3 (1–2.2) .04 
CVC present 72 (29.6) 21 (22.1) 51 (34.5) .04
Percentage of CVC removed 67 (93.1) 21 (100) 46 (90.2) .31
Source/site of infection
Primary bacteremia 40 (16.5) 13 (13.7) 27 (18.2) .35
Central line–associated bacteremia 70 (28.8) 22 (23.2) 48 (32.4) .12
Infection of prosthetic material 26 (10.7) 11 (11.6) 15 (10.1) .72
Skin & soft tissue infection 33 (13.6) 9 (9.5) 24 (16.2) .13
Surgical site infections 16 (6.6) 3 (3.2) 13 (8.8) .05
Osteomyelitis 40 (16.5) 20 (21.1) 20 (13.5) .12
Septic arthritis/prosthetic joint infection 28 (11.5) 12 (12.6) 16 (10.8) .66
Epidural abscess 13 (5.4) 6 (6.3) 7 (4.7) .59








niversity at St Louis user on 09 O
ctober 2020
4 • ofid • Hamad et al
joint infections in 40 (16%) patients and were determined to 
be primary bacteremia in 40 (16%) patients. Ninety-three per-
cent (67) of CVCs were removed in patients with concurrent 
bacteremia, and 7 (30%) cardiac implantable electronic devices 
(CIEDs) were removed. Patients were treated for a median (in-
terquartile range [IQR]) of 42 (34–44) days from the time of 
culture clearance or source control achievement (Table 1). One 
hundred thirty-nine patients (93.2%) on ceftriaxone received 
2 g daily, while 10 patients (6.8%) received 2 g every 12 hours.
Comparison of the Treatment Groups
Patients in the ceftriaxone and oxacillin-cefazolin groups had 
similar overall baseline and clinical characteristics. However, 
the ceftriaxone group had lower rates of intensive care unit care 
(29.1% vs 48.4%; P < .01), shorter duration of bacteremia (1.3 
vs 1.7 days; P = .04), and shorter intravenous antibiotic duration 
(median [IQR], 42 [28–43] vs 42 [42–44] days; P =  .01). The 
ceftriaxone group also had lower rates of valvular heart diseases 
(13% vs 33.7%; P < .01), TEEs performed (25% vs 59%; P < .01), 
endocarditis (28.4% vs 43.2%; P =  .02), and subsequent valve 
replacement surgeries (1.4% vs 15.8%; P < .01), but had more 
solid tumors (29.1% vs 8.4%; P < .01) (Table 1). Both groups had 
similar rates of discharge to post–acute care facilities (34.5% vs 
33.7%; P =  .90). Of patients discharged on IV ceftriaxone, 23 
(16%) received oxacillin or cefazolin for more than 48 hours 
while inpatient. Patients in the oxacillin-cefazolin group were 
more likely to have received oral antibiotics for suppression 
after the end of OPAT (25 [26%] vs 19 [13%]; P ≤ .01) (Table 1). 
The most common antibiotics used for suppression were doxy-
cycline 26 (60%), cephalexin 11 (26%), and trimethoprim/sul-
famethoxazole 3 (7%).
Outcomes
The primary composite outcome (death, readmission related 
to MSSA infection, or microbiological failure within 90 days 
of hospital discharge) occurred in 49 (20%) of patients. 
Microbiological failure occurred in 15 (6%), 90-day all-cause 
mortality occurred in 22 (9%), and hospital readmission due 
to MSSA infection occurred in 23 (10%) patients. Changes in 
antibiotics due to toxicity occurred in 11 (4.5%) patients, 6 
(4.1%) in the ceftriaxone group and 4 (4.2%) in the oxacillin-
cefazolin group (P =  .95). Toxicities in the ceftriaxone group 
were skin rashes in 3 patients (1 with concomitant eosino-
philia), acute kidney injury in 2, and nausea in 1, while in the 
oxacillin-cefazolin group, the reasons for switch were neutro-
penia in 2 patients and acute kidney injury and hepatotoxicity 
in 1 each. There were no significant differences in microbio-
logical failure (6 [6.3%] vs 9 [6.1%]; P = .94), 90-day all-cause 
mortality (7 [7.4%] vs 15 [10.1%]; P =  .46), readmission due 
to an MSSA infection (10 [10.5%] vs 13 [8.8%]; P  =  .65), or 
composite outcome (18 [19%] vs 31 [21%]; P = .70) among the 
oxacillin-cefazolin and ceftriaxone treatment groups, respec-
tively (Table 1).
Variable, No. (%) or Median (IQR) Total (n = 243) Oxacillin-Cefazolin (n = 95 [39%])  Ceftriaxone (n = 148 [61%]) P Value
Valve replaced 17 (7) 15 (15.8) 2 (1.4) <.01
Inpatient antibiotics received >48 h
Ceftriaxone 80 (32) 0 80 (53) <.01
Oxacillin 53 (21) 40 (41) 13 (9) <.01
Cefazolin 33 (13) 23 (24) 10 (7) <.01
Cefepime 3 (1) 0 3 (2) .28
Meropenem 12 (5) 3 (3) 9 (6) .38
Piperacillin-tazobactam 8 (3) 2 (2) 6 (4) .49
Vancomycin 25 (10) 7 (7) 18 (12) .24
Linezolid 4 (2) 3 (3) 1 (1) .30
Inpatient laboratory values at discharge
CRP 145 (68–223) 131 (54–199) 156 (71–234) .32
ESR 71 (45–95) 71 (38–94) 71 (53–97) .24
White blood count 7.9 (5.7–10.6) 7.9 (5.6–10) 8 (5.7–10.9) .75
Platelets 262 (157–367) 295 (159–393) 245 (154–332) .11
Creatinine clearance 97 (66–132) 88 (54–128) 102 (73–134) .10
Oral antibiotic suppression after OPAT 44 (18.1) 25 (26) 19 (13) <.01
Outcomes
Change in antibiotics due to toxicity 11 (4.5) 4 (4.2) 6 (4.1) .95
Microbiological failure 15 (6.2) 6 (6.3) 9 (6.1) .94
90-d all-cause mortality 22 (9.1) 7 (7.4) 15 (10.1) .46
Readmitted due to MSSA infection 23 (9.5) 10 (10.5) 13 (8.8) .65
Composite 49 (20.2) 18 (19) 31 (21) .70
Abbreviations: CHF, congestive heart failure; CIED, cardiovascular implantable electronic device; CRP, C-reactive protein; CVC, central venous catheter; ESR, erythrocyte sedimentation 
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In the Cox regression model, the use of ceftriaxone was not 
associated with composite outcome of treatment failure in ei-
ther univariate (hazard ratio [HR], 1.062; 95% CI, 0.594–1.898) 
or multivariate analysis (HR, 0.994; 95% CI, 0.537–1.841) 
(Table 2).
Endocarditis Subgroup
Most patients (228 [94%]) underwent transthoracic echocar-
diography (TTE), while 93 (38%) underwent transesophageal 
echocardiography (TEE) to evaluate for endocarditis. 
Endocarditis was suspected in 83 (34%) patients with con-
comitant MSSA BSI. Echocardiography confirmed the suspi-
cion in 54 (65%) patients, while 29 (35%) did not have a TEE 
done and were treated for endocarditis. Forty-two (50.6%) were 
treated with ceftriaxone, while 41 (49.4%) were treated with ox-
acillin/cefazolin. When analyzing the endocarditis group, the 
ceftriaxone group had higher rates of 90-day all-cause mortality 
(6 [14.3%] vs 1 [2.4%]; P  =  .11) and composite outcome (11 
[25.6%] vs 4 [10%]; P = .17). The risks of microbiological failure 
and hospital readmission due to MSSA infection did not differ 
between the 2 groups (Table 3).
DISCUSSION
Although widely accepted as standard treatment for MSSA BSI, 
the quality of evidence for preferential use of antistaphylococcal 
beta-lactam antibiotics like oxacillin, nafcillin, or cefazolin is 
poor and relies mostly on observational data [10]. At our in-
stitution, ceftriaxone is increasingly being used to treat MSSA 
infections. This practice, driven by practical implications of 
cost and convenience of outpatient treatment, was evaluated 
in a retrospective review done at our institution of 124 MSSA 
osteoarticular infections that documented favorable treatment 
outcomes with ceftriaxone [6, 14].
This study demonstrates that in selected patients discharged 
on OPAT, ceftriaxone is a viable option for MSSA BSI when 
compared with oxacillin and cefazolin. We did not detect a 
difference in the composite outcome for treatment failure (in-
cluding mortality, readmissions due to infection, and microbi-
ological failure) between the oxacillin/cefazolin group (19%) 
and the ceftriaxone group (21%; P = .70) (Table  1). These re-
sults were very similar to the retrospective study of 93 male 
patients with MSSA bacteremia by Patel et  al., where there 
were no significant differences between patients treated with 
ceftriaxone (n = 42) compared with those treated with nafcillin 
or cefazolin (n = 51) in either microbiological (95.2% vs 94.1%; 
P = .81) or clinical cure rates (83.3% vs 74.5%; P = .30). Our re-
sults conflict with those of Carr et al., who reported significantly 
higher failure rates among patients with MSSA BSI receiving 
ceftriaxone (n = 33) compared with cefazolin (n = 38; 54.5% 
vs 28.9%; P = .029). However, in this study, there were more 
patients on ceftriaxone who were discharged to an external 
skilled nursing facility (SNF) as compared with an attached 
community living center (CLC), which was shown to be a risk 
factor for treatment failure. The authors argue that the differ-
ence could be due to closer monitoring and availability of ID 
physicians in the attached CLC compared with the SNF. In our 
study, the rates of discharge to post–acute care facilities (34.5% 
vs 33.7%; P = .90) were similar in both the comparison groups, 
but there was a trend for treatment failure in patients discharged 
to a post–acute care facility (HR, 1.769) (Table 2). Suboptimal 
outcomes (eg, unplanned hospitalizations or line-associated in-
fections) have been described in patients discharged on OPAT 
to post–acute care facilities and could indicate a gap in the con-
tinuity of care and adequate laboratory monitoring of adverse 
events [15, 16].
Although there were no significant differences in the failure 
rates between the 2 groups in our study overall, among the 
subgroup of patients with endocarditis there was a trend to-
ward more adverse events in the ceftriaxone group (25.6% vs 
10%; P = .17). Possible reasons could be that the higher min-
imal inhibitory concentration distributions of ceftriaxone 
tend to be associated with a lower MSSA bactericidal 
Table 2. Multivariable Risk Factors Associated With Treatment Failure 
(Composite of Death and Clinical/Microbiological Failure)
Variable
Multivariate Analysis
Hazard Ratio 95% CI P Value
Age >65 y 0.907 0.484–1.700 .76
Elixhauser Comorbidity Index 1.015 0.993–1.039 .19
Endocarditis 0.884 0.471–1.660 .70
Lack of source control 1.080 0.426–2.737 .87
Discharged on ceftriaxone 0.994 0.537–1.841 .99
Discharge to post–acute care facility 1.769 0.974–3.214 .06
Table 3.  Outcomes of the Ceftriaxone Group vs Oxacillin-Cefazolin Group in Patients Diagnosed With Endocarditis
Outcome Variables Total (n = 83), No. (%) Oxacillin-Cefazolin (n = 41), No. (%) Ceftriaxone (n = 42), No. (%) P Value
Microbiological failure 6 (7.2) 3 (7.3) 3 (7.1) .99
90-d all-cause mortality 7 (8.4) 1 (2.4) 6 (14.3) .11
Readmitted due to MSSA infection 6 (7.2) 3 (7.3) 3 (7.1) .99
Composite 15 (18.1) 4 (10) 11 (25.6) .17
Change in antibiotics due to toxicity after discharge 1 (1.2) 0 1 (2.4) .99
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effect when compared with cefazolin in pharmacodynamics 
models, and such an effect might have greater implications 
in endocarditis patients [17]. Our microbiology laboratory 
tests for cefoxitin susceptibility as a surrogate for cefazolin, 
ceftriaxone, and oxacillin susceptibilities, consistent with the 
Clinical and Laboratory Standards Institute guidelines [18]. 
In a study evaluating pharmacokinetic/pharmacodynamic 
end points of commonly used antibiotics for S.  aureus, 5% 
of MSSA isolates tested were ceftriaxone-nonsusceptible and 
in a modeling-based prediction tool; for ceftriaxone, only a 
higher dose of 2000 mg q12h produced a cumulative fraction 
of response (CFR) ≥90% [19]. Another pharmacologic argu-
ment is that ceftriaxone is highly protein bound (up to 95%) 
and hence has decreased free drug available to exhibit anti-
bacterial activity, especially when maintaining a high serum 
level is needed to penetrate deeper tissues such as vegetations 
in endocarditis. However, cefazolin is around 80% protein 
bound, and oxacillin is around 94% protein bound, so this 
theory should affect all the 3 antibiotics of interest equally 
[20]. Although not statistically significant, given the trend 
for worse outcomes in patients with endocarditis and the 
plausible pharmacodynamic arguments to explain this, 
twice-daily ceftriaxone therapy should be further studied in 
this setting. The overall 90-day mortality (9%) in our cohort 
was lower when compared with studies in the United States 
that have reported 90-day mortality (25%–26%) in S. aureus 
bacteremias [17, 21]. This is likely due to the fact that we in-
cluded patients who survived the inpatient stay and were well 
enough to be discharged on OPAT.
There are several limitations to this study. This is a ret-
rospective single-center study, and we are unable to prove 
noninferiority of ceftriaxone. We would need 332 patients in 
each treatment arm, with estimated 85% survival, accepting a 
10% difference in outcomes, to have 95% power (with α = .025) 
to prove noninferiority [22]. There could be a difference in the 
treatment outcomes that we are unable to detect due to the rel-
atively small numbers in our study. However, we feel that this 
reflects a pragmatic comparison of 2 concurrent treatment 
practices in our institution. We observed significant differences 
in the baseline characteristics between the 2 treatment groups, 
likely due to a selection bias of certain infectious disease phys-
icians’ preference of using oxacillin/cefazolin for complicated 
bacteremia. The oxacillin/cefazolin group had a higher propor-
tion of patients with endocarditis (43.2% vs 28.4%; P  =  .02), 
longer length of stay (median days, 15.3 vs 7.4), and longer 
duration of bacteremia (median days, 1.7 vs 1.3). Oxacillin/
nafcillin and cefazolin are recommended by treatment guide-
lines endorsed by the Infectious Diseases Society of America for 
treating MSSA endocarditis, and it is likely that physicians when 
treating endocarditis follow guideline-recommended antibiotic 
selection [23]. The ceftriaxone group had fewer cases of endo-
carditis, and this may have led to outcomes in the ceftriaxone 
group being inherently better than in the comparator group. We 
did not see significant differences in outcomes between treat-
ment groups even after adjusting for different factors including 
antibiotic choice and endocarditis in the multivariable model. 
Another limitation is that this study addresses the question of 
antibiotic choice after discharge from the hospital (OPAT) and 
does not compare the antibiotic choices made while inpatient. 
We felt that this was a more relevant question to answer, as 
ceftriaxone offers more convenient dosing and has a cost ad-
vantage, which makes it an attractive option for OPAT [6]. In 
the study by Wieland et al., the median cost estimate for the an-
tibiotic course was significantly lower in the ceftriaxone group 
compared with the oxacillin group ($6720 vs $11 329; P < .001). 
We were also not able to make meaningful comparisons re-
garding the optimal dosing for use of ceftriaxone due to the 
sparse number of patients (<7%) receiving doses >2 g/d. There 
is a concern that the broader coverage of ceftriaxone compared 
with oxacillin and cefazolin would lead to antibiotic resistance 
and would be against good stewardship practice. Lastly, there is 
a possibility of poor adherence to OPAT therapy, and this was 
not measured for the study participants.
Despite these limitations, this is the largest study to date com-
paring ceftriaxone with other antibiotics of interest in MSSA 
bacteremia. Infectious Disease physicians saw all included pa-
tients, and hence there is some degree of homogeneity in the 
workup, management, and treatment duration of these patients. 
In a recent survey of OPAT patients at our institution, receiving 
a simpler regimen once or twice daily was significantly associ-
ated with better adherence when compared with more frequent 
dosing regimens (76% vs 17% of the adherent and nonadherent 
groups, respectively; P = .01) [24]. Thus, patients are more likely 
to adhere to ceftriaxone as compared with more frequent dosing 
regimens of oxacillin or cefazolin. Furthermore, once-daily 
regimens facilitate patients receiving therapy at an infusion 
center, which is the only outpatient option for Medicare patients 
without a significant out-of-pocket cost [22]. The results of this 
study would be encouraging especially for Medicare patients 
and for those centers that offer self-directed OPAT, where cost 
and ease of dosing are important considerations [25, 26].
CONCLUSIONS
Ceftriaxone might be a reasonable alternative for the treat-
ment of patients with MSSA bacteremia discharged on OPAT, 
and when compared with oxacillin or cefazolin, no significant 
difference in outcomes was noted in this retrospective study. 
There was a trend toward adverse outcomes in patients with en-
docarditis, although it was not statistically significant. Further 
studies, possibly prospective comparisons, should be under-
taken to further document clinical equivalence, optimal dosing, 
and cost effectiveness of ceftriaxone considering the advantages 








niversity at St Louis user on 09 O
ctober 2020
Ceftriaxone Use in MSSA Bacteremia • ofid • 7
Acknowledgments
The authors would like to acknowledge Dr. Carey-Ann D. Burnham, PhD, 
for her insightful comments and for the reviewing manuscript and Dr. 
Yvonne Burnett, PharmD, for her care of select patients and maintaining the 
OPAT registry at the Washington University Infectious Disease Division. 
We also thank Katelin Nickel for her statistical advice and Dottie Sinclair 
for help with informatics and data management.
Financial support. The authors did not receive any funding to conduct 
this study.
Potential conflicts of interest. All authors: no reported conflicts of 
interest. All authors have submitted the ICMJE Form for Disclosure of 
Potential Conflicts of Interest. Conflicts that the editors consider relevant to 
the content of the manuscript have been disclosed.
References
1. Naber  CK, Baddour  LM, Giamarellos-Bourboulis  EJ, et  al. Clinical consensus 
conference: survey on gram-positive bloodstream infections with a focus on 
Staphylococcus aureus. Clin Infect Dis 2009; 48:S260–70.
2. van Hal SJ, Jensen SO, Vaska VL, et al. Predictors of mortality in Staphylococcus 
aureus bacteremia. Clin Microbiol Rev 2012; 25:362–86.
3. Thwaites  GE, Edgeworth  JD, Gkrania-Klotsas  E, et  al; UK Clinical Infection 
Research Group. Clinical management of Staphylococcus aureus bacteraemia. 
Lancet Infect Dis 2011; 11:208–22.
4. Winans SA, Luce AM, Hasbun R. Outpatient parenteral antimicrobial therapy for 
the treatment of methicillin-susceptible Staphylococcus aureus: a comparison of 
cefazolin and ceftriaxone. Infection 2013; 41:769–74.
5. Food and Drug Administration. Ceftriaxone Package. Available at: https://www.
accessdata.fda.gov/drugsatfda_docs/label/2014/065169s022lbl.pdf. Accessed 12 
February 2020.
6. Wieland BW, Marcantoni JR, Bommarito KM, et al. A retrospective comparison 
of ceftriaxone versus oxacillin for osteoarticular infections due to methicillin-
susceptible Staphylococcus aureus. Clin Infect Dis 2012; 54:585–90.
7. Patel UC, McKissic EL, Kasper D, et al. Outcomes of ceftriaxone use compared 
to standard of therapy in methicillin susceptible staphylococcal aureus (MSSA) 
bloodstream infections. Int J Clin Pharm 2014; 36:1282–9.
8. Carr D, Bonomo RA, Stiefel U, Sims S. Cefazolin versus ceftriaxone for the treat-
ment of methicillin-susceptible Staphylococcus aureus bacteremia in a tertiary-
care Veterans Affairs medical center. Open Forum Infect Dis 2015; 5:XXX–XX.
9. Lother  SA, Press  N. Once-daily treatments for methicillin-susceptible 
Staphylococcus aureus bacteremia: are they good enough? Curr Infect Dis Rep 
2017; 19:1–8.
10. Holland TL, Arnold C, Fowler VG Jr. Clinical management of Staphylococcus au-
reus bacteremia: a review. JAMA 2014; 312:1330–41.
11. Harris  PA, Taylor  R, Thielke  R, et  al. Research Electronic Data Capture 
(REDCap)—a metadata-driven methodology and workflow process for pro-
viding translational research informatics support. J Biomed Inform 2009; 
42:377–81.
12. Moore BJ, White S, Washington R, et al. Identifying increased risk of readmis-
sion and in-hospital mortality using hospital administrative data: the AHRQ 
Elixhauser Comorbidity Index. Med Care 2017; 55:698–705.
13. Schoenfeld D. Partial residuals for the proportional hazards regression model on 
JSTOR. Biometrika 1982; 69:239–241.
14. Tice  AD, Rehm  SJ, Dalovisio  JR, et  al; IDSA. Practice guidelines for outpa-
tient parenteral antimicrobial therapy. IDSA guidelines. Clin Infect Dis 2004; 
38:1651–72.
15. Schmidt M, Hearn B, Gabriel M, et al. Predictors of unplanned hospitalization in 
patients receiving outpatient parenteral antimicrobial therapy across a large inte-
grated healthcare network. Open Forum Infect Dis 2017; 4:XXX–XX.
16. Huang V, Ruhe JJ, Lerner P, Fedorenko M. Risk factors for readmission in patients 
discharged with outpatient parenteral antimicrobial therapy: a retrospective co-
hort study. BMC Pharmacol Toxicol 2018; 19:1–9.
17. Musta AC, Riederer K, Shemes S, et al. Vancomycin MIC plus heteroresistance 
and outcome of methicillin-resistant Staphylococcus aureus bacteremia: trends 
over 11 years. J Clin Microbiol 2009; 47:1640–4.
18. Clinical and Laboratory Standards Institute. Performance Standards for 
Antimicrobial Susceptibility Testing. 29th ed. M100-S29. Wayne, PA: Clinical and 
Laboratory Standards Institute; 2019.
19. Housman  ST, Sutherland  CA, Nicolau  DP. Pharmacodynamic profile of com-
monly utilised parenteral therapies against meticillin-susceptible and meticillin-
resistant Staphylococcus aureus collected from US hospitals. Int J Antimicrob 
Agents 2014; 44:235–41.
20. Van  der  Auwera  P, Klastersky  J. Study of the influence of protein binding on 
serum bactericidal titres and killing rates in volunteers receiving ceftazidime, 
cefotaxime and ceftriaxone. J Hosp Infect 1990; 15:23–34.
21. Shurland  S, Zhan  M, Bradham  DD, Roghmann  MC. Comparison of mortality 
risk associated with bacteremia due to methicillin-resistant and methicillin-
susceptible Staphylococcus aureus. Infect Control Hosp Epidemiol 2007; 28:273–9.
22. Sealed Envelope, Ltd. 2012. Power calculator for binary outcome non-inferiority 
trial. Available at: https://www.sealedenvelope.com/power/binary-noninferior/. 
Accessed 13 October 2019.
23. Baddour  LM, Wilson  WR, Bayer  AS, et  al; American Heart Association 
Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease of the 
Council on Cardiovascular Disease in the Young, Council on Clinical Cardiology, 
Council on Cardiovascular Surgery and Anesthesia, and Stroke Council. Infective 
endocarditis in adults: diagnosis, antimicrobial therapy, and management of com-
plications: a scientific statement for healthcare professionals from the American 
Heart Association. Circulation 2015; 132:1435–86.
24. Hamad Y, Dodda S, Frank A, et al. Perspectives of patients on outpatient paren-
teral antimicrobial therapy: experiences and adherence. Open Forum Infect Dis 
2020; 7:XXX–XX.
25. Diamante  O, Bhavan  K. Retrospective comparison of self-administered 
ceftriaxone vs cefazolin for methicillin-susceptible Staphylococcus aureus bacte-
remia in an outpatient antibiotic therapy setting. Open Forum Infect Dis 2014; 
1:S206.
26. Bhavan KP, Brown LS, Haley RW. Self-administered outpatient antimicrobial in-
fusion by uninsured patients discharged from a safety-net hospital: a propensity-









niversity at St Louis user on 09 O
ctober 2020
